ArticleClinical, cosmetic and investigational dermatology2021
Use of Botulinum Toxin in Treating Rosacea: A Systematic Review.
Article in Clinical, cosmetic and investigational dermatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 33 citations in OpenAlex.
- Trial
- Targeting Neurovascular Inflammation in Rosacea: A Systematic Review of Botulinum Toxin Therapy.Cureus · 2026Review
- Botulinum Toxin Vascular Effectiveness: Low or High Doses?Aesthetic plastic surgery · 2026Review
- Therapeutic Efficacy and Safety of Botulinum Toxin Type A in Erythematotelangiectatic Rosacea: A Systematic Review.Cureus · 2026Review
- [Botulinum toxin preparations in dermatology : Characterization, comparison, and treatment options].Dermatologie (Heidelberg, Germany) · 2026Review
- Botulinum Toxin Type A in Red Ear Syndrome and a Novel Multi-nerve Injection Paradigm: A Case Report.Cureus · 2025Article
- Managing a Burning Face: Clinical Manifestations and Therapeutic Approaches for Neurogenic Rosacea.International journal of molecular sciences · 2025Review
- Article
- Poly-d,l-Lactic Acid Via Transdermal Microjet Drug Delivery for Treating Rosacea in Asian Patients.Journal of cosmetic dermatology · 2024Article
- The Efficacy and Safety of Botulinum Toxin A for the Treatment of Rosacea: A Systematic Review.Cureus · 2023Review
- Exploring the Pathogenesis and Mechanism-Targeted Treatments of Rosacea: Previous Understanding and Updates.Biomedicines · 2023Review
- Subjective and Objective Measurements of the Facial Effects of Microdoses of Botulinum Toxin.Dermatology practical & conceptual · 2023Article
- Botulinum neurotoxins: Future innovations.Medicine · 2023Article
- Rosacea Aggravated after Intracutaneous Injection of Poly-L-lactic Acid through a Stamp-type Microneedle.Plastic and reconstructive surgery. Global open · 2022Article
- Botulinum Toxin A Alleviates Persistent Erythema and Flushing in Patients with Erythema Telangiectasia Rosacea.Dermatology and therapy · 2022Article
- Role of Botulinum Toxin in the Management of Topical Corticosteroid Induced Rosacea Like Dermatitis: A Case Report.Indian dermatology online journalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRosacea is a chronic skin disorder characterized by erythema, flushing, telangiectasia, papules and pustules, phymatous changes, and ocular involvement. The aim of this study was to examine all published research articles in which botulinum toxin was used to treat rosacea and to evaluate the efficacy and safety of this treatment.
methodsPubMed, Embase, Cochrane Library, and Web of Science database were used to identify articles eligible for systematic review on March 26, 2021. Prospective or retrospective studies which directly used botulinum toxin to treat rosacea were included and reviewed.
resultsNine studies were included in this systematic review. Two were randomized controlled trials, graded as Level 2 for the quality of evidence. The total number of participants was 130, and the number of participants in each study ranged from 1 to 25. The improvement was observed in all studies in signs and symptoms compared with baseline. Adverse events were transitory and self-limited.
conclusionBotulinum toxin could have overall satisfying efficacy and safety in the treatment of rosacea, though limited by small sample size, imperfect study design, and short follow-up visits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.